Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

@article{Pinter2009SorafenibIU,
  title={Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.},
  author={Matthias Pinter and Wolfgang Sieghart and Ivo W. Graziadei and Wolfgang Vogel and Andreas Maieron and Robert Koenigsberg and Adalbert Weissmann and Gabriela Verena Kornek and Christina Plank and Markus Peck-Radosavljevic},
  journal={The oncologist},
  year={2009},
  volume={14 1},
  pages={70-6}
}
BACKGROUND Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis. METHODS Between May 2006 and December 2007, we treated 59 patients (Child-Pugh class A/B/C, 26/23/10) with unresectable HCC with sorafenib (daily target dose, 400 mg twice daily). Data were collected retrospectively. Survival curves were calculated via the Kaplan-Meier method. RESULTS One patient (Child-Pugh class B) had a partial… CONTINUE READING